Puma Biotechnology, Inc.
PBYI
$3.00
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.19% | 6.30% | -4.77% | -3.59% | 3.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.19% | 6.30% | -4.77% | -3.59% | 3.34% |
| Cost of Revenue | 2.75% | 35.53% | 8.43% | 4.74% | 13.77% |
| Gross Profit | -3.98% | -2.98% | -8.86% | -6.29% | 0.01% |
| SG&A Expenses | -10.24% | -14.14% | -9.05% | -5.84% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.42% | 3.58% | -1.89% | -0.60% | 1.54% |
| Operating Income | -6.91% | 27.71% | -26.76% | -21.37% | 15.83% |
| Income Before Tax | 6.29% | 441.16% | 677.24% | 207.78% | 4,861.49% |
| Income Tax Expenses | -670.45% | 69.44% | 93.81% | 104.60% | 138.02% |
| Earnings from Continuing Operations | 40.23% | 525.26% | 457.52% | 219.91% | 1,079,450.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.23% | 525.26% | 457.52% | 219.91% | 1,079,450.00% |
| EBIT | -6.91% | 27.71% | -26.76% | -21.37% | 15.83% |
| EBITDA | -5.12% | 20.72% | -16.72% | -13.50% | 16.14% |
| EPS Basic | 34.91% | 537.28% | 439.42% | 202.04% | 15,796.55% |
| Normalized Basic EPS | -0.52% | 63.31% | -33.27% | -27.70% | 26.24% |
| EPS Diluted | 37.38% | 569.02% | 387.62% | 207.75% | 5,198.85% |
| Normalized Diluted EPS | -0.30% | 62.87% | -34.10% | -28.23% | 25.59% |
| Average Basic Shares Outstanding | 3.22% | 3.41% | 3.69% | 3.82% | 5.52% |
| Average Diluted Shares Outstanding | 2.55% | 3.03% | 3.55% | 4.00% | 6.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |